Key facts
- AAX Biotech’s last known valuation is $4.1M (Oct 2024).
- It has raised $1.2M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Jinderman & Partners, DRIVE ( KI Innovations Business Incubator), HJKK Didrikson, Karolinska Institutet, Karolinska Institutet Holding — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AAX Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for AAX Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AAX Biotech
Developer of antibody technologies intended for cancer, autoimmune diseases, and neurological diseases. The company's technology provides improved antibody characterization through high-resolution, high-throughput epitope mapping, helping healthcare professionals by making it easy to produce antibody-based medicines and enabling other antibody-developing companies to excel in solving their technical difficulties.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2020
- Employees
- 9
- Website
- aaxbiotech.com/
- Ownership
- Privately Held (backing)
AAX Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AAX Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AAX Biotech in its N-PORT filings yet. We sweep new filings monthly.